Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Apatinib + Nab-Paclitaxel in Advanced Gastric Cancer
NCT06339216Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in gastric cancer (GC), sponsored by Chinese PLA General Hospital. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06339216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339216.